Wave Life Sciences Ltd. (NASDAQ:WVE) is among the 12 Best Genomics Stocks to Invest In.
TheFly reports that on December 19, 2025, H.C. Wainwright upgraded Wave Life Sciences Ltd. (NASDAQ:WVE)’s price target from $22 to $30. Analyst Andrew Fein upheld the Buy rating. H.C. Wainwright cited 9.4% visceral fat loss and 3.2% lean mass gain with no gastrointestinal problems to support WVE-007 as a possible body recomposition agent, using key opinion leader validation and dose-response modeling. According to the firm, higher doses may expedite fat loss, and a clean safety profile supports a distinct commercial label.
Visible Alpha reported on the same day that Wave Life Sciences Ltd. (NASDAQ:WVE) shares soared by 147% on December 8 following the company’s presentation of preliminary clinical data for WVE-007, an RNA-based obesity therapy. Three months after a single dose, early data from a small research study revealed sustained fat reduction, including drops in visceral and total fat.
Visible Alpha consensus forecasts that risk-adjusted revenue for WVE-007 is expected to increase from $26 million to approximately $68 million in 2030 and from $1 billion to $2.1 billion by 2040. It is anticipated that by 2040, the drug candidate will account for 15% of the company’s revenue, climbing to 47%. The company’s total revenue is projected to reach $459 million in 2030 and $4.5 billion by 2040.
Wave Life Sciences Ltd. (NASDAQ:WVE) is a clinical-stage biotechnology firm dedicated to achieving the vast promise of RNA therapies, commonly known as oligonucleotides, which target RNA to transform human health.
While we acknowledge the potential of WVE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.
Disclosure. None
